Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California, USA.
J Invest Dermatol. 2010 Jan;130(1):221-9. doi: 10.1038/jid.2009.195.
Fatty acid-binding protein-7 (FABP7) has been shown to be expressed in cutaneous melanoma; however, its role in tumor progression is unclear. Expression of FABP7 was assessed during melanoma progression through assessment of various clinicopathology stages of primary tumor progression and metastasis. FABP7 mRNA was highly expressed in 60 of 87 (69%) primary melanomas, compared with significant (P<0.0001) reduction in 13 of 68 (19%) metastatic melanomas. Analysis of 37 paired primary and metastatic melanomas by immunohistochemistry with anti-FABP7 Ab showed 73 and 27% positivity, respectively (P<0.001). FABP7 detection of metastatic tissues was inversely correlated with relapse-free (P<0.0001) and overall (P<0.0001) survival. To examine FABP7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using microsatellite markers encompassing the FABP7 gene. LOH was identified in 10 of 20 (50%) metastatic melanomas at 6q22.31, compared with 0 of 14 primary melanomas (P=0.0017). FABP7 as a surrogate biomarker for circulating tumor cells (CTCs) in the blood was assessed by quantitative real-time (qRT)-PCR from melanoma patients' blood (n=134). Assessment of patients' blood showed that FABP7(+) CTC decreased with disease progression. FABP7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood.
脂肪酸结合蛋白 7（FABP7）已被证实存在于皮肤黑色素瘤中；然而，其在肿瘤进展中的作用尚不清楚。通过评估原发性肿瘤进展和转移的各种临床病理阶段，评估 FABP7 在黑色素瘤进展过程中的表达。与 68 例转移性黑色素瘤中的 13 例（19%）相比，60 例 87 例（69%）原发性黑色素瘤中 FABP7 mRNA 表达高度上调。对 37 对原发性和转移性黑色素瘤进行免疫组织化学分析，用抗 FABP7 Ab 显示分别为 73%和 27%阳性（P<0.001）。转移性组织中 FABP7 的检测与无复发生存（P<0.0001）和总生存（P<0.0001）呈负相关。为了研究晚期黑色素瘤中 FABP7 表达缺失，使用微卫星标记物评估 FABP7 基因的杂合性缺失（LOH）。在 20 例转移性黑色素瘤中的 10 例（50%）中鉴定出 6q22.31 的 LOH，而在 14 例原发性黑色素瘤中无 1 例（P=0.0017）。通过定量实时（qRT）-PCR 从黑色素瘤患者的血液（n=134）中评估 FABP7 作为血液中循环肿瘤细胞（CTC）的替代生物标志物。对患者血液的评估表明，FABP7（+）CTC 随疾病进展而减少。FABP7 可能作为肿瘤进展基因发挥作用，并可作为血液中早期黑色素瘤全身性扩散的潜在诊断生物标志物。
